View all video statements held in occasion of half-year and full-year results.

Quarterly CEO statement Q3 - 2025/26

Ypsomed reached multiple strategic milestones in Q3 2025/26:

  • Three new product platforms were launched, and the recyclable autoinjector YpsoLoop won the CPHI Innovation Award.
  • Ypsomed announced the new clinical excellence program “Clear-to-Clinic”.
  • Five drugs launched in Ypsomed devices in Q3 2025/26.
  • The manufacturing expansion is well underway in the US and in China.

Go to press release

Ypsomed reached multiple strategic milestones in Q3 2025/26:

  • Three new product platforms were launched, and the recyclable autoinjector YpsoLoop won the CPHI Innovation Award.
  • Ypsomed announced the new clinical excellence program “Clear-to-Clinic”.
  • Five drugs launched in Ypsomed devices in Q3 2025/26.
  • The manufacturing expansion is well underway in the US and in China.

Go to press release

Half-Year Results 2025/26

Ypsomed grows by 21% in the first half of 2025/26 in the core business

  • Substantial growth in autoinjectors commercial sales of 46.2%;
  • Successfully completed the sales of Ypsomed Diabetes Care AG;
  • Filled 189 new positions worldwide, thereof 45 in Switzerland;
  • Announced the location of our new U.S. facility in Holly Springs, North Carolina in October;
  • Successfully completed the sale of Ypsotec AG.

Go to the event

Ypsomed grows by 21% in the first half of 2025/26 in the core business

  • Substantial growth in autoinjectors commercial sales of 46.2%;
  • Successfully completed the sales of Ypsomed Diabetes Care AG;
  • Filled 189 new positions worldwide, thereof 45 in Switzerland;
  • Announced the location of our new U.S. facility in Holly Springs, North Carolina in October;
  • Successfully completed the sale of Ypsotec AG.

Go to the event

View previous video statements
Browse presentations